Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Riad SalemDaneng LiNicolas SommerSairy HernandezWendy VerretBeiying DingRiccardo LencioniPublished in: Cancer medicine (2021)
These data highlight the improved ORR, DpR, and CR rates with ATEZO/BEV in unresectable HCC.